Policy Solutions for Enhancing Drug Pricing Transparency and Reducing Health Care Costs in the United States

The excessive cost of prescription pharmaceuticals in the United States is an often-recognized issue for consumers, healthcare providers, and insurance companies alike. A major contributing factor to excess cost is the lack of transparency in drug pricing, which makes it difficult for stakeholders to understand the actual costs of medications. In this article, we look at two basic policy measures to ameliorate this issue. First, we explore providing consumers with clear information on medication costs at the point of prescription, specifically in outpatient doctors' offices. This policy seeks to empower patients and enhance informed decision-making by integrating drug cost information into electronic health records (EHRs), allowing physicians to discuss cost-effective alternatives with their patients. Second, we investigate potential federal regulations that would require pharmaceutical companies to publicly disclose reasons for price hikes, using specific benchmarks as guidelines. These regulations would mandate pharmaceutical companies to report heavy price increases and the factors contributing to these hikes, thereby holding manufacturers accountable and promoting price stability. By addressing these two policy measures, the article aims to enhance drug price transparency and reduce healthcare costs.